Assembly Biosciences Shares Outstanding 2010-2024 | ASMB
Assembly Biosciences shares outstanding from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Assembly Biosciences Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
5 |
| 2022 |
4 |
| 2021 |
4 |
| 2020 |
3 |
| 2019 |
2 |
| 2018 |
2 |
| 2017 |
1 |
| 2016 |
1 |
| 2015 |
1 |
| 2014 |
1 |
| 2013 |
0 |
| 2012 |
0 |
| 2011 |
0 |
| 2010 |
0 |
| 2009 |
0 |
Assembly Biosciences Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-06-30 |
6 |
| 2024-03-31 |
5 |
| 2023-12-31 |
5 |
| 2023-09-30 |
4 |
| 2023-06-30 |
4 |
| 2023-03-31 |
4 |
| 2022-12-31 |
4 |
| 2022-09-30 |
4 |
| 2022-06-30 |
4 |
| 2022-03-31 |
4 |
| 2021-12-31 |
4 |
| 2021-09-30 |
4 |
| 2021-06-30 |
4 |
| 2021-03-31 |
3 |
| 2020-12-31 |
3 |
| 2020-09-30 |
3 |
| 2020-06-30 |
3 |
| 2020-03-31 |
3 |
| 2019-12-31 |
2 |
| 2019-09-30 |
2 |
| 2019-06-30 |
2 |
| 2019-03-31 |
2 |
| 2018-12-31 |
2 |
| 2018-09-30 |
2 |
| 2018-06-30 |
2 |
| 2018-03-31 |
2 |
| 2017-12-31 |
1 |
| 2017-09-30 |
1 |
| 2017-06-30 |
1 |
| 2017-03-31 |
1 |
| 2016-12-31 |
1 |
| 2016-09-30 |
1 |
| 2016-06-30 |
1 |
| 2016-03-31 |
1 |
| 2015-12-31 |
1 |
| 2015-09-30 |
1 |
| 2015-06-30 |
1 |
| 2015-03-31 |
1 |
| 2014-12-31 |
1 |
| 2014-09-30 |
1 |
| 2014-06-30 |
0 |
| 2014-03-31 |
0 |
| 2013-12-31 |
0 |
| 2013-09-30 |
0 |
| 2013-06-30 |
0 |
| 2013-03-31 |
0 |
| 2012-12-31 |
0 |
| 2012-09-30 |
0 |
| 2012-06-30 |
0 |
| 2012-03-31 |
0 |
| 2011-12-31 |
0 |
| 2011-09-30 |
0 |
| 2011-06-30 |
0 |
| 2011-03-31 |
0 |
| 2010-12-31 |
0 |
| 2010-09-30 |
0 |
| 2010-06-30 |
0 |
| 2010-03-31 |
0 |
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.107B |
$0.007B |
|
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
|
